SuperGen Initiates Dosing in Phase I Trial of Novel Tyrosine Kinase Inhibitor

A A

SuperGen announced that its collaborators, The Translational Genomics Research Institute and TGen Clinical Research Services, dosed the first patient in a Phase I clinical trial of MP470, a novel, oral, multitargeted tyrosine kinase inhibitor to fight tumors.

The trial is expected to enroll roughly 30 patients at two study centers, SuperGen said.

The Phase I trial is an accelerated-titration, dose-escalation study designed to assess the safety and tolerability of MP470, and to determine the maximum tolerated dose of the compound in patients with advanced-stage solid tumors.

Additionally, the company said it will assess pharmacokinetic and biomarker data from the study to assist in designing follow-on clinical studies for the use of MP470 as a single-agent and in combination treatment modalities.